The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-Zika virus set to spread across Americas, spurring vaccine hunt

Mon, 25th Jan 2016 17:14

* Mosquito-borne virus linked to birth defects in Brazil

* Brazil's Butantan Institute aims to develop vaccine

* GSK and Sanofi reviewing vaccine possibilities

* More research needed into potential sexual transmission (Adds comment from GlaxoSmithKline and Sanofi, graphic link)

By Tom Miles and Ben Hirschler

GENEVA/LONDON, Jan 25 (Reuters) - The mosquito-borne Zikavirus, which has been linked to brain damage in thousands ofbabies in Brazil, is likely to spread to all countries in theAmericas except for Canada and Chile, the World HealthOrganization said on Monday.

Zika transmission has not yet been reported in thecontinental United States, although a woman who fell ill withthe virus in Brazil later gave birth to a brain-damaged baby inHawaii.

Brazil's Health Ministry said in November that Zika waslinked to a foetal deformation known as microcephaly, in whichinfants are born with smaller-than-usual brains.

Brazil has reported 3,893 suspected cases of microcephaly,the WHO said last Friday, over 30 times more than in any yearsince 2010 and equivalent to 1-2 percent of all newborns in thestate of Pernambuco, one of the worst-hit areas.

The Zika outbreak comes hard on the heels of the Ebolaepidemic in West Africa, demonstrating once again howlittle-understood diseases can rapidly emerge as global threats.

"We've got no drugs and we've got no vaccines. It's a caseof deja vu because that's exactly what we were saying withEbola," said Trudie Lang, a professor of global health at theUniversity of Oxford. "It's really important to develop avaccine as quickly as possible."

Large drugmakers' investment in tropical disease vaccineswith uncertain commercial prospects has so far been patchy,prompting health experts to call for a new system of incentivesfollowing the Ebola experience.

"We need to have some kind of a plan that makes (companies)feel there is a sustainable solution and not just a one-shotdeal over and over again," Francis Collins, director of the U.S.National Institutes of Health, said last week.

The Sao Paulo-based Butantan Institute is currently leadingthe research charge on Zika and said last week it planned todevelop a vaccine "in record time", although its director warnedthis was still likely to take three to five years.

British drugmaker GlaxoSmithKline said on Monday itwas studying the feasibility of using its vaccine technology onZika, while France's Sanofi said it was reviewingpossibilities.

RIO CONCERNS

The virus was first found in a monkey in the Zika forestnear Lake Victoria, Uganda, in 1947, and has historicallyoccurred in parts of Africa, Southeast Asia and the PacificIslands. But there is little scientific data on it and it isunclear why it might be causing microcephaly in Brazil.

Laura Rodrigues of the London School of Hygiene and TropicalMedicine said it was possible the disease could be evolving.

If the epidemic was still going on in August, when Brazil isdue to host the Olympic Games in Rio de Janeiro, then pregnantwomen should either stay away or be obsessive about covering upagainst mosquito bites, she said.

The WHO advised pregnant women planning to travel to areaswhere Zika is circulating to consult a healthcare providerbefore travelling and on return.

The clinical symptoms of Zika are usually mild and oftensimilar to dengue, a fever which is transmitted by the sameAedes aegypti mosquito, leading to fears that Zika will spreadinto all parts of the world where dengue is commonplace.

More than one-third of the world's population lives in areasat risk of dengue infection, in a band stretching throughAfrica, India, Southeast Asia and Latin America.

Zika's rapid spread, to 21 countries and territories in theAmericas since May 2015, is due to the prevalence of Aedesaegypti and a lack of immunity among the population, the WHOsaid in a statement.

RISK TO GIRLS

Like rubella, which also causes mild symptoms but can leadto birth defects, health experts believe a vaccine is needed toprotect girls before they reach child-bearing age.

Evidence about other transmission routes, apart frommosquito bites, is limited.

"Zika has been isolated in human semen, and one case ofpossible person-to-person sexual transmission has beendescribed. However, more evidence is needed to confirm whethersexual contact is a means of Zika transmission," the WHO said.

While a causal link between Zika and microcephaly has notyet been definitively proven, WHO Director-General Margaret Chansaid the circumstantial evidence was "suggestive and extremelyworrisome".

In addition to finding a vaccine and potential drugs tofight Zika, some scientists are also planning to take the fightto the mosquitoes that carry the disease.

Oxitec, the UK subsidiary of U.S. synthetic biology companyIntrexon, hopes to deploy a self-limiting geneticallymodified strain of insects to compete with normal Aedes aegypti.

Oxitec says its proprietary OX513A mosquito succeeded inreducing wild larvae of the Aedes mosquito by 82 percent in anarea of Brazil where 25 million of the transgenic insects werereleased between April and November. Authorities reported a bigdrop in dengue cases in the area.

(Editing by Mark Trevelyan)

More News
12 Feb 2024 08:35

TOP NEWS: GSK's bepirovirsen receives US FDA fast track designation

(Alliance News) - GSK PLC on Monday said that the US health watchdog granted fast track designation for its bepirovirsen treatment for chronic hepatitis B.

Read more
12 Feb 2024 07:50

LONDON BRIEFING: Tritax Big Box, UK Commercial Property agree merger

(Alliance News) - Equities in London are called to open higher on Monday, with inflation readings from the US and UK on the horizon, which could drive equity market sentiment during the remainder of the week.

Read more
12 Feb 2024 07:21

GSK gets FDA fast track for chronic hepatitis B treatment

(Sharecast News) - GSK announced on Monday that bepirovirsen, an investigational antisense oligonucleotide (ASO) aimed at treating chronic hepatitis B (CHB), had been granted fast track designation by the US Food and Drug Administration (FDA).

Read more
9 Feb 2024 09:15

LONDON BROKER RATINGS: Deutsche Bank cuts AstraZeneca to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
6 Feb 2024 08:51

TOP NEWS: GSK reports positive news on trio of high profile products

(Alliance News) - GSK PLC on Tuesday delivered a triple dose of positive updates on some of its leading products, Arexvy, Shingrix and Blencep.

Read more
6 Feb 2024 07:47

LONDON BRIEFING: BP promises buyback despite drop in profit

(Alliance News) - Stocks in London are called to open higher, ahead of a slew of construction purchasing managers' index readings from the eurozone, the UK and Germany.

Read more
6 Feb 2024 07:23

GSK reports positive myeloma trial results, progresses vaccine applications

(Sharecast News) - GSK reported progress in its trial of a myeloma treatment on Tuesday, as well as regulatory progress around its shingles vaccine in China and its RSV vaccine in the United States.

Read more
1 Feb 2024 09:27

TOP NEWS: GSK maintains "vigorous" defence after settling Zantac case

(Alliance News) - GSK PLC on Thursday insisted upon its scientific integrity, after reaching another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
1 Feb 2024 09:11

GSK settles Zantac case in California without admitting liability

(Sharecast News) - GSK announced on Thursday that it had reached a confidential settlement to effectively resolve the legal case over Zantac filed in a California state court.

Read more
1 Feb 2024 09:03

LONDON BROKER RATINGS: Barclays cuts Next; JPMorgan raises easyJet

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
1 Feb 2024 07:42

LONDON BRIEFING: Shell profit falls; announces USD3.5 billion buyback

(Alliance News) - Stocks in London are set to follow New York into the red, after the US Federal Reserve quashed hopes of a March cut to interest rates and ahead of the Bank of England interest rate decision.

Read more
31 Jan 2024 17:05

LONDON MARKET CLOSE: Stocks mixed hours before expected US Fed hold

(Alliance News) - Stock prices in London closed mixed on Wednesday in a trade-thinned day ahead of the US Federal Reserve interest rate decision this evening.

Read more
31 Jan 2024 15:49

London close: Stocks mixed ahead of US Fed, BoE decisions

(Sharecast News) - London's financial markets finished with mixed performance on Wednesday, with investors closing their wallets ahead of rate announcements from both the US Federal Reserve and the Bank of England.

Read more
31 Jan 2024 12:05

LONDON MARKET MIDDAY: FTSE 100 flat ahead of Federal Reserve decision

(Alliance News) - The FTSE 100 in London was flat heading into Wednesday afternoon, as the US Federal Reserve's latest interest rate decision edges closer, keeping equity market enthusiasm to a minimum.

Read more
31 Jan 2024 09:13

TOP NEWS: GSK profit up on Arexvy boost in 2023 but total payout down

(Alliance News) - GSK PLC reported an increase in profit and revenue for 2023 as revenue for HIV medicine had stable growth, amid optimism in the company's outlook.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.